Dementia Market

Market Overview:

The 7 major dementia markets reached a value of US$ 6.8 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 12.8 Billion by 2034, exhibiting a growth rate (CAGR) of 5.85% during 2024-2034.

The dementia market has been comprehensively analyzed in IMARC's new report titled "Dementia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Dementia is a progressive syndrome that affects cognitive function, particularly memory, thinking, and reasoning. It is caused by damage to or degeneration of brain cells and can lead to a decline in a person's ability to perform daily activities and communicate effectively. The most common symptoms of this ailment include memory loss, fluctuations in mood and behavior, difficulty with language and communication, etc. Individuals with dementia may have trouble performing routine tasks, such as getting dressed or preparing meals, and may experience personality changes, confusion, and disorientation. Diagnosing dementia involves a combination of medical evaluation, cognitive assessments, and diagnostic testing. A healthcare professional will typically begin by conducting a thorough medical history, physical examination, and cognitive testing to assess memory, language, and problem-solving abilities. Several additional diagnostic procedures, including brain imaging and blood tests, may also be ordered to help rule out other possible causes of cognitive decline.

The increasing cases of traumatic brain injuries and the growing prevalence of neurodegenerative disorders, such as Parkinson's disease and Alzheimer's disease, are primarily driving the dementia market. In addition to this, the rising incidences of several associated risk factors, including advancing age, genetic mutations, high blood pressure, buildup of abnormal protein deposits in the brain, etc., are also bolstering the market growth. Furthermore, the widespread adoption of antipsychotic medications, such as risperidone, olanzapine, quetiapine, etc., to treat symptoms like agitation, aggression, and hallucinations that often accompany the ailment is acting as another significant growth-inducing factor. Additionally, the inflating utilization of cholinesterase inhibitors, which work by increasing the levels of neurotransmitter acetylcholine in the brain, is further augmenting the market growth. Moreover, the escalating demand for non-pharmacological interventions, including cognitive stimulation therapy, music therapy, physical exercise, etc., to enhance cognitive function, mood, and behavior is also creating a positive outlook for the market. Apart from this, the introduction of advanced imaging techniques that detect changes in the brain's structure and function, such as the accumulation of amyloid plaques and tau tangles, is expected to drive the dementia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the dementia market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for dementia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the dementia market in any manner.

Recent Developments:

• In April 2024, Cognition Therapeutics Inc. reported that it had reached its target enrollment in the randomized, placebo-controlled Phase 2 SHIMMER (COG1201) study (NCT05225415), which is looking at the safety and efficacy of CT1812 in people with mild-to-moderate dementia with Lewy bodies (DLB).
• In December 2023, Passage Bio, Inc. announced preliminary safety and biomarker results from three Cohort 1 patients in the ongoing global Phase 1/2 upliFT-D clinical study evaluating PBFT02, an adeno-associated virus-delivery gene therapy for the management of frontotemporal dementia with granulin (GRN) mutations.
• In July 2023, Arkuda Therapeutics disclosed that the firm will present pre-clinical results on lead development candidate ARKD-104 for the therapy of GRN-related frontotemporal dementia (FTD-GRN) at the 2023 Alzheimer's Association International Conference.

Key Highlights:

• Dementia affects around 55 million individuals globally, with more than 60% living in low- and middle-income countries.
• In high-income nations, only 20-50% of dementia cases are diagnosed and documented in primary care.
• Dementia affects around 8.8 million Indians aged 60 and up.
• The global population affected by dementia is estimated to reach 8.5 billion in 2030, rising to 9.7 billion in 2050 and 11.2 billion by 2100.
• Furthermore, dementia is more common among women than males by around twice.

Drugs:

Aricept is the first and only FDA-approved prescription medicine for the treatment of all stages of Alzheimer's disease, including mild, moderate, and severe dementia. Aricept may function differently for each individual. For individuals who respond, symptoms may improve, stabilize, or worsen more slowly than they would without Aricept. Aricept is currently available as 5 mg, 10 mg, orally disintegrating tablets (5 mg and 10 mg), and 23 mg tablets.

PR006 is being developed as a possibly disease-modifying single-dose gene therapy for individuals with frontotemporal dementia with GRN mutations (FTD-GRN). PR006 is intended to delay or stop disease progression in FTD-GRN patients by boosting progranulin levels through the introduction of a healthy GRN gene to the central nervous system. PR006 is delivered via injection into the cisterna magna using the well-studied viral vector AAV9.

DNL593 is a replacement treatment for frontotemporal dementia caused by granulin gene abnormalities. DNL593 employs a brain shuttle technology, also known as a protein transfer vehicle (PTV), to restore brain progranulin levels, which transports intravenously delivered protein across the blood-brain barrier into the central nervous system. Protein transfer vehicles were designed to carry BACE-1 antibodies into the brain but can also transport other payloads.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the dementia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the dementia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current dementia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the dementia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the dementia market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the dementia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of dementia across the seven major markets?
• What is the number of prevalent cases (2018-2034) of dementia by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of dementia by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of dementia by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with dementia across the seven major markets?
• What is the size of the dementia patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of dementia?
• What will be the growth rate of patients across the seven major markets?
   

Dementia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for dementia drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the dementia market?
• What are the key regulatory events related to the dementia market?
• What is the structure of clinical trial landscape by status related to the dementia market?
• What is the structure of clinical trial landscape by phase related to the dementia market?
• What is the structure of clinical trial landscape by route of administration related to the dementia market?